Phase I/II – First Administration

453 trials 190 recruiting

Filter these 453 trials by condition, country, sponsor and more.

Open in Search →

A clinical trial to investigate EO4010, a novel cancer vaccine therapy, with an immune checkpoint blocker, in patients with previously treat… Ended

2023-509509-62-00 Patients with unresectable, previously treated locally 2023-05-03
A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy you… Ended

2022-502308-66-00 Healthy volunteers (prevention of influenza infection) 2023-04-27
First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended

2022-501183-17-00 Non-Small Cell Lung Cancer 2023-02-23
A clinical study to evaluate mRNA-3705 in Patients with MMA Ended

2022-502492-32-00 Isolated Methylmalonic Acidemia Due to Methylmalonyl-Co 2023-02-03
A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutatio… Ended

2024-513062-19-00 Metastatic or recurrent melanoma 2022-12-22
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy and in Com… Ended

2022-502419-12-00 Malignant Solid Tumors 2022-11-02
Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing Ended

2024-511976-34-00 "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted 2022-10-31
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS Ended

2024-516711-24-00 Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinom 2022-10-18
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo… Ended

2024-511750-53-00 Unresectable Locally Advanced or Metastatic Cancer 2022-09-08
TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Ended

2024-517307-37-00 Oncology 2022-09-01
Study investigating the safety and efficacy of a new iodine formulation called DLQ03 in a wound-healing model in patients with atopic eczema Ended

2022-500647-21-00 Atopic dermatitis (Eczema) 2022-08-04
Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumours Ended

2024-512866-32-00 Solid tumors 2022-07-12
First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk… Ended

2023-508357-58-00 Acute lymphocytic leukaemia- Acute myeloid leukaemia re 2022-07-04
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Ended

2023-504441-31-00 gastric adenocarcinoma or adenocarcinoma of the gastroe 2022-06-29
A Phase I/II Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fab… Ended

2024-512695-34-00 Fabry Disease (X-linked lysosomal storage disease). 2022-06-28
Treatment of adult Wilson's Disease patients with gene therapy Ended

2023-509998-23-00 Wilson's Disease 2022-06-21
A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended

2023-504363-17-00 Advanced MTAP-null solid tumors 2022-05-13
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Ended

2023-508954-25-00 Advanced solid tumors (squamous cell carcinoma of the h 2022-05-11
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended

2024-512639-58-00 Solid Tumors 2022-05-07
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low… Ended

2024-514758-65-00 metastatic castration-resistant prostate cancer (mCRPC) 2022-05-04
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ended

2022-501686-47-00 relapsed/refractory chronic lymphocytic leukemia relaps 2022-02-28
A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-in-human (FIH) Proof of Concept (PoC) study to… Ended

2023-507743-11-00 Netherton syndrome (NS) 2022-02-18
GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended

2024-510722-10-00 Malignant Solid Tumors 2021-12-13
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended

2023-510511-19-00 Advanced Solid Tumors 2021-11-08